Research
Hormonal
Gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, are frequent side effects of tirzepatide, particularly during initiation and titration phases.
GI side effects like nausea and diarrhea are common with tirzepatide, especially when starting or increasing the dose. Talk to your doctor about managing these symptoms with diet changes or medication to help you stay on treatment.
ModerateSupportsMEDIUM confidence
Gastrointestinal (GI) events, including nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal pain, resulted in a total of 18,018 reports.
Why this rating
Based on FAERS data, which is subject to reporting bias.
Source
Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025)
Hadi A. Almansour et al. · Healthcare · 2025
DOI 10.3390/healthcare13182259
cohort · n=65974Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide use is strongly associated with a high frequency of dosing errors, particularly incorrect dose administration, which increases significantly over time and correlates with strong statistical safety signals.Moderate
- Tirzepatide is associated with injection-site reactions, particularly pain, which are consistent with the class of GLP-1/GIP agonists and are typically mild and transient.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →